C12N 2770/36111
Alphavirus
Official title: Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
C12N2770/36111 (Alphavirus) appears on 545 US grants and 837 published applications in this corpus.
Search patents in C12N- Granted patents
- 545
- Published applications
- 837
- Assignees
- 318
- Inventors
- 1,177
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 5 | 0 |
| 1997 | 2 | 0 |
| 1998 | 12 | 0 |
| 1999 | 8 | 0 |
| 2000 | 10 | 0 |
| 2001 | 14 | 2 |
| 2002 | 17 | 13 |
| 2003 | 15 | 26 |
| 2004 | 9 | 23 |
| 2005 | 2 | 19 |
| 2006 | 12 | 20 |
| 2007 | 10 | 21 |
| 2008 | 14 | 23 |
| 2009 | 10 | 20 |
| 2010 | 15 | 26 |
| 2011 | 11 | 34 |
| 2012 | 14 | 19 |
| 2013 | 18 | 26 |
| 2014 | 15 | 35 |
| 2015 | 13 | 21 |
| 2016 | 19 | 27 |
| 2017 | 20 | 27 |
| 2018 | 20 | 21 |
| 2019 | 19 | 36 |
| 2020 | 20 | 53 |
| 2021 | 31 | 43 |
| 2022 | 38 | 76 |
| 2023 | 61 | 79 |
| 2024 | 38 | 68 |
| 2025 | 28 | 48 |
| 2026 | 19 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/36141Use of virus, viral particle or viral elements as a vectorIndexing code298
- C12N 2770/36134Use of virus or viral component as vaccineIndexing code186
- C12N 2770/36122New viral proteins or individual genes, new structural or functional aspects ofIndexing code184
- C12N 2770/36161Methods of inactivation or attenuationIndexing code81
- C12N 2770/36123Virus like particles [vlp]Indexing code59
- C12N 2770/36151Methods of production or purification of viral materialIndexing code54
- C12N 2770/36121Viruses as suchIndexing code41
- C12N 2770/36171Demonstrated in vivo effectIndexing code33
All 12 subgroupsShow fewer
Recent patents
- Cytokine immunotherapy22 Sep 2026US 12,742,182 B2VLP Therapeutics, LLC
- Prostate neoantigens and their uses28 Jul 2026US 12,692,513 B2Janssen Biotech, Inc.
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Human monoclonal antibodies to Venezuelan equine encephalitis virus and uses therefor2 Jun 2026US 12,642,847 B2Vanderbilt University
- Galectin-targeting immunotherapy26 May 2026US 12,636,341 B2VLP Therapeutics, LLC
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
- Dna vaccine for fish against salmonid alphavirus27 Aug 2026US 2026/0248901 A1Intervet Inc.
- Treatment of atopic dermatitis using self-replicating rna expressing il-3120 Aug 2026US 2026/0240967 A1Ceva Sante Animale
- Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp320 Aug 2026US 2026/0240977 A1Valneva SE
- Nanobiosensor and preparation method thereof and virus antibody detection method using same13 Aug 2026US 2026/0235602 A1National Defense Medical University
Most cited
By later US patents
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998
- Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes185US 5,316,931 ABiosource Genetics Corporation · 1994
- Alphavirus vector constructs167US 5,843,723 AChiron Corporation · 1998
- Alphavirus structural protein expression cassettes152US 5,789,245 AChiron Corporation · 1998
- Eukaryotic layered vector initiation systems126US 6,015,686 AChiron Viagene, Inc. · 2000